产品属性:
产品名称 | A-9758 |
规格 | 100mg、250mg、500mg |
货号 | EY-01Y10467 |
Cas No.: 2055271-22-0
别名: N/A
化学名: N/A
分子式: C25H23Cl2F3N2O3
分子量: 527.36
溶解度: Soluble in DMSO
储存条件: Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述:
A-9758 is a RORγ ligand and a potent, selective RORγt inverse agonist (IC50=5 nM), and exhibits robust potency against IL-17A release. A-9758 is effective in suppressing both Th17 differentiation and Th17 effector function. A-9758 significantly attenuates IL-23 driven psoriasiform dermatitis and is effective in blocking skin and joint inflammation[1].IC50: 5 nM (RORγt), 73 nM (RORα), 1370 nM (RORβ)[1]A-9758 inhibits human, mouse, dog and rat RORγ transactivation (IC50=38 nM, 20 nM, 25 nM and 64 nM, respectively)[1].A-9758 displays a cofactor profile in recruiting co-repressors (NCoR1: EC50=60 nM, NCoR2: EC50=43 nM) and derecruiting co-activators (NCoA1: IC50=110 nM, PGC1α: IC50=49 nM)[1].A-9758 inhibits TCR-mediated IL-17A secretion with an IC50 of 100 and 38 nM for human CD4+ T cells and in vitro differentiated mouse Th17 cells, respectively. A-9758 attenuates the differentiation of RORγt expressing Th17 cells and/or their effector function[1].[1]. Gauld S, et al. Inhibition of IL-23 mediated inflammation with a novel small molecule inverse agonist of RORgt. J Pharmacol Exp Ther. 2019 Aug 2. pii: jpet.119.258046.
特别提醒公司产品仅供科研使用